|
1.
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Blagosklonny MV: P53 from complexity to
simplicity: mutant p53 stabilization, gain-of-function, and
dominant-negative effect. FASEB J. 14:1901–1907. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Resnick MA and Inga A: Functional mutants
of the sequence-specific transcription factor p53 and implications
for master genes of diversity. Proc Natl Acad Sci USA.
100:9934–9939. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Monti P, Ciribilli Y, Jordan J, Menichini
P, Umbach DM, Resnick MA, Luzatto L, Inga A and Fronza G:
Transcriptional Functionality of germ line p53 mutants infuences
cancer phenotype. Clin Cancer Res. 13:3789–3795. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Varley JM, McGown G, Thorncroft M, James
LA, Margison GP, Forster G, Evans DGR, Harris M, Kelsey AM and
Birch JM: Are there low-penetrance TP53 alleles? Evidence from
childhood adrenocortical tumors. Am J Hum Genet. 65:995–1006. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ribeiro RC, Sandrini F, Figueiredo B,
Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M,
Cadwell C, Sampaio G, et al: An inherited p53 mutation that
contributes in a tissue-specific manner to pediatric adrenal
cortical carcinoma. Proc Natl Acad Sci USA. 98:9330–9335. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Zambetti GP: The p53 mutation ‘gradient
effect’ and its clinical implications. J Cell Physiol. 213:370–373.
2007.
|
|
8.
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamura R and Ishioka C: Understanding the function-structure
and function-mutation relatiohship of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar
|
|
9.
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
North S, Pluquet O, Maurici D,
El-Ghissassi F and Hainaut P: Restoration of wild-type conformation
and activity of a temperature-sensitive mutant of p53 (p53(V272M))
by the cytoprotective aminothiol WR1065 in the esophageal cancer
cell line TE-1. Mol Carcinog. 33:181–188. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Maurici D, Monti P, Campomenosi P, North
S, Frebourg T, Fronza G and Hainaut P: Amifostine (WR2721) restores
transcriptional activity of specific p53 mutant proteins in a yeast
functional assay. Oncogene. 20:3533–3540. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Di Como C and Prives C: Human
tumor-derived p53 proteins exhibit binding site selectivity and
temperature sensitivity for transactivation in yeast-based assay.
Oncogene. 19:2527–2539. 1998.PubMed/NCBI
|
|
13.
|
Bullock AN, Henckel J and Fersht AR:
Quantitative analysis of residual folding and DNA binding in mutant
p53 core domain: definition of mutant states for rescue in cancer
therapy. Oncogene. 19:1245–1256. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Shiraishi K, Kato S, Han SY, Liu W, Otsuka
K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ochuchi N and
Ishioka C: Isolation of temperature-sensitive p53 mutations from a
comprehensive missense mutation library. J Biol Chem. 279:348–355.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Dearth LR, Qian H, Wang T, Baroni TE, Zeng
J, Chen SW, Yi SY and Brachmann RK: Inactive full-length p53
mutants lacking dominant wild-type p53 inhibition highlight loss of
heterozygosity as an important aspect of p53 status in human
cancers. Carcinogenesis. 28:289–298. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Joerger AC and Fersht AR:
Structure-function-rescue: the diverse nature of common p53 cancer
mutants. Oncogene. 26:2226–2242. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Grochova D, Vankova J, Damborsky J,
Ravcukova B, Smarda J, Vojtesek B and Smardova J: Analysis of
transactivation capability and conformation of p53
temperature-dependent mutants and their reactivation by amifostine
in yeast. Oncogene. 27:1243–1252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Slovackova J, Grochova D, Navratilova J,
Smarda J and Smardova J: Transactivation by temperature-dependent
p53 mutants in yeast and human cells. Cell Cycle. 9:2141–2148.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Ishioka C, Frebourg T, Yan Yx, Vidal M,
Friend SH, Schmidt S and Iggo R: Screening patients for
heterozygous p53 mutations using a functional assay in yeast. Nat
Genet. 5:124–129. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Flaman JM, Frebourg T, Moreau V,
Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron
L, Benhattar J, et al: A simple p53 functional assay for screening
cell lines, blood, and tumors. Proc Natl Acad Sci USA.
92:3963–3967. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Smardova J, Nemajerova A, Trbusek M,
Vagunda V and Kovarik J: Rare somatic p53 mutation identified in
breast cancer: a case report. Tumor Biol. 22:59–66. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Friedlander P, Haupt Y, Prives C and Oren
M: A mutant p53 that discriminates between p53-responsive genes
cannot induce apoptosis. Mol Cell Biol. 16:4961–4971.
1996.PubMed/NCBI
|
|
23.
|
Navratilova J, Horvath V, Kozubik A, Lojek
A, Lipsick J and Smarda J: p53 arrest growth and induces
differentiation of v-Myb-transformed monoblasts. Differentiation.
75:592–604. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Pavlova S, Mayer J, Koukalova H and
Smardova J: High frequency of temperature-sensitive mutations of
p53 tumor suppressor in acute myeloid leukemia revealed by
functional assay in yeast. Int J Oncol. 23:121–131. 2003.PubMed/NCBI
|
|
25.
|
Campomenosi P, Monti P, Aprile A,
Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA,
Iggo R and Fronza G: p53 mutants can ften transactivate promoters
containing a p21 but not Bax or PIG3 responsive elements. Oncogene.
20:3573–3579. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Flaman JM, Robert V, Lenglet S, Moreau V,
Iggo R and Frebourg T: Identification of human p53 mutations with
differential effects on the bax and p21 promoters using functional
assay in yeast. Oncogene. 16:1369–1272. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Inga A, Monti P, Fronza G, Darden T and
Resnick M: p53 mutants exhibiting enhanced transcriptional
activation and altered promoter selectivity are revealed using a
sensitive, yeast-based functional assay. Oncogene. 20:501–513.
2001. View Article : Google Scholar
|
|
28.
|
Fulci G, Ishii N, Maurici D, Gernert KM,
Hainaut P, Kaur B and Van Metr EG: Initiation of human astrocytoma
by clonal evolution of cells with progressive los sof p53 functions
in a patient with a 283H TP53 germ-line mutation: Evidence for
precursor lesion. Cancer Res. 62:2897–2905. 2002.PubMed/NCBI
|
|
29.
|
Hansen S, Hupp TR and Lane DP: Allosteric
regulation of the thermostability and DNA binding activity of human
p53 by specific interacting proteins. J Biol Chem. 271:3917–3924.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Xirodimas DP and Lane DP: Molecular
evolution of the thermosensitive PAb1620 epitope of human p53 by
DNA shuffling. J Biol Chem. 274:28042–28049. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Cho Y, Gorina S, Jeffrey PD and Pavletich
NP: Crystal structure of a p53 tumor suppressor-DNA complex:
understanding tumorigenic mutations. Science. 265:346–355. 1994.
View Article : Google Scholar : PubMed/NCBI
|
